Lantheus Holdings, Inc. filed an 8-K on November 10, 2026, disclosing that on November 8, 2026, it entered into a definitive agreement to sell its contract development and manufacturing organization business and its Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp.
Key Highlights
- Definitive agreement signed: Lantheus Holdings entered into a definitive agreement with PharmaLogic Holdings Corp. on November 8, 2026.
- Assets being sold: The sale covers Lantheus's CDMO business and its Springfield, New Jersey manufacturing facility.
- Closing conditions apply: The sale is described as subject to customary closing conditions, according to the filing.
- Transition services: Lantheus will provide certain transition services to PharmaLogic immediately following the closing.
- Long-term supply agreement: The parties will enter into a long-term supply agreement under which PharmaLogic's therapeutic CDMO franchise, Agilera, will manufacture lutetium Lu 177 dotatate for Lantheus.
Lantheus Discloses CDMO Sale and Long-Term Supply Arrangement with PharmaLogic
According to the filing, Lantheus Holdings, Inc. (NASDAQ:LNTH), a Delaware corporation headquartered in Bedford, Massachusetts, entered into a definitive agreement on November 8, 2026, to divest its contract development and manufacturing organization business along with its Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp. The company disclosed the transaction under Item 8.01 (Other Events) of the Form 8-K filed on November 10, 2026.
The filing states that the sale is subject to customary closing conditions and that Lantheus will provide certain transition services to PharmaLogic immediately following the closing. No financial terms of the transaction, such as a purchase price, were disclosed in the filing.
In connection with the sale, the filing notes that the parties will also enter into a long-term supply agreement. Under that agreement, PharmaLogic's therapeutic CDMO franchise, Agilera, will manufacture lutetium Lu 177 dotatate for Lantheus. The filing contains forward-looking statements subject to the company's cautionary language, noting that risks include the possibility that closing conditions may not be satisfied, that the transaction may involve unexpected costs or delays, and that anticipated benefits may not be fully realized or may take longer to realize than expected. The filing was signed by Daniel M. Niedzwiecki, Chief Administrative Officer and General Counsel, on November 9, 2026.
What Was Disclosed
Lantheus Holdings disclosed a definitive agreement to sell its CDMO business and Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp., alongside a long-term supply agreement for lutetium Lu 177 dotatate manufacturing through PharmaLogic's Agilera franchise. No purchase price was disclosed.



Please wait processing your request...